Explore

Trendline Trendline
IGC Pharma Completes Enrollment for Phase 2 CALMA Trial on Alzheimer's Agitation

IGC Pharma Completes Enrollment for Phase 2 CALMA Trial on Alzheimer's Agitation

IGC Pharma Completes Enrollment for Phase 2 CALMA Trial on Alzheimer's Agitation
Trendline Trendline
IGC Pharma Completes Enrollment for Phase 2 CALMA Trial Targeting Alzheimer's Agitation

IGC Pharma Completes Enrollment for Phase 2 CALMA Trial Targeting Alzheimer's Agitation

IGC Pharma Completes Enrollment for Phase 2 CALMA Trial Targeting Alzheimer's Agitation
Trendline Trendline
CNS Drug Discovery Market Projected to Reach $27.55 Billion by 2035

CNS Drug Discovery Market Projected to Reach $27.55 Billion by 2035

CNS Drug Discovery Market Projected to Reach $27.55 Billion by 2035
Trendline Trendline
Erasca Faces Class Action Lawsuit Following Stock Decline Due to Clinical Data Disclosure

Erasca Faces Class Action Lawsuit Following Stock Decline Due to Clinical Data Disclosure

Erasca Faces Class Action Lawsuit Following Stock Decline Due to Clinical Data Disclosure
Trendline Trendline
Parabilis and Kailera IPOs Signal Renewed Optimism in Biotech Sector

Parabilis and Kailera IPOs Signal Renewed Optimism in Biotech Sector

Parabilis and Kailera IPOs Signal Renewed Optimism in Biotech Sector
Trendline Trendline
Ascendiant Capital Markets Raises IGC Pharma Price Target Amid Clinical Advances

Ascendiant Capital Markets Raises IGC Pharma Price Target Amid Clinical Advances

Ascendiant Capital Markets Raises IGC Pharma Price Target Amid Clinical Advances
Trendline Trendline
Antengene Receives IND Approval for ATG-201 in China for Autoimmune Disease Treatment

Antengene Receives IND Approval for ATG-201 in China for Autoimmune Disease Treatment

Antengene Receives IND Approval for ATG-201 in China for Autoimmune Disease Treatment
Trendline Trendline
SonoThera Secures $125 Million to Advance Genetic Medicine Development

SonoThera Secures $125 Million to Advance Genetic Medicine Development

SonoThera Secures $125 Million to Advance Genetic Medicine Development
Trendline Trendline
Incyte to Acquire Vega Therapeutics for $2 Billion, Expanding Hematology Pipeline with Phase III Candidate

Incyte to Acquire Vega Therapeutics for $2 Billion, Expanding Hematology Pipeline with Phase III Candidate

Incyte to Acquire Vega Therapeutics for $2 Billion, Expanding Hematology Pipeline with Phase III Candidate
Trendline Trendline
Adoption of Whole-Genome Deep Sequencing Rises in Gene-Edited Therapies

Adoption of Whole-Genome Deep Sequencing Rises in Gene-Edited Therapies

Adoption of Whole-Genome Deep Sequencing Rises in Gene-Edited Therapies
Trendline Trendline
Investors Eye Opportunities in GLP-1 Drug Innovation Amidst Rapid Advancements

Investors Eye Opportunities in GLP-1 Drug Innovation Amidst Rapid Advancements

Investors Eye Opportunities in GLP-1 Drug Innovation Amidst Rapid Advancements
Trendline Trendline
N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease

N-Zyme Biomedical Initiates Phase 2 Trial for Pepsin Inhibitor in Reflux Disease